Wave Life Sciences Ltd. (NASDAQ: WVE) has secured a late‑breaking oral presentation slot for its RestorAATion‑2 clinical trial data at the American Thoracic Society (ATS) International Conference in Orlando, Florida. The acceptance, announced on March 6 2026, positions the company to present new 400‑mg multidose and 600‑mg single‑dose cohort data during the conference’s May 15‑20 session.
The presentation is scheduled for Monday, May 18, 2026, at 4:03 p.m. ET. The data will include the 400‑mg multidose cohort and the 600‑mg single‑dose cohort, providing a comprehensive view of dose‑response and safety for the RNA‑editing therapy WVE‑006.
"The annual ATS conference is an important forum for fostering innovation in pulmonary care, and we are excited to have the opportunity to share data from our RestorAATion‑2 trial, including our upcoming 400 mg multidose data and 600 mg single dose data." – Paul Bolno, President and CEO.
WVE‑006 is an RNA‑editing therapy that corrects the single G‑to‑A point mutation in the SERPINA1 gene responsible for alpha‑1 antitrypsin deficiency (AATD). The therapy is part of Wave’s PRISM platform, which enables stereopure oligonucleotide development across multiple modalities. The acceptance of a late‑breaking presentation signals that the company’s data have met the rigorous standards of a major pulmonary society and provides a platform to engage regulators and investors ahead of a potential accelerated‑approval pathway.
Wave regained full rights to WVE‑006 from GSK in February 2026, allowing the company to accelerate its regulatory strategy. The company remains on track to deliver additional higher‑dose datasets from the RestorAATion‑2 trial throughout the year and to present data from the INLIGHT trial of WVE‑007 for obesity later this month.
The acceptance of the late‑breaking oral presentation is a key milestone in Wave’s roadmap toward a public data release and regulatory engagement. By showcasing the 400‑mg and 600‑mg cohort data at a high‑profile conference, Wave aims to strengthen its case for accelerated approval and to reinforce investor confidence in its first‑in‑class RNA‑editing platform.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.